Innovent Biologics (HK:1801) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innovent Biologics has received approval from China’s National Medical Products Administration for its new drug, DOVBLERON, a next-generation ROS1 inhibitor for treating advanced ROS1-positive non-small cell lung cancer. This addition bolsters Innovent’s portfolio and offers a promising option for patients with limited treatment choices. The approval follows successful trials demonstrating DOVBLERON’s efficacy in addressing unmet needs in lung cancer treatment.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.